Sedivention Secures €2.9 Million Seed Funding for Cryo‑Based Obesity Treatment

*TL;DR: Sedivention closed a €2.9 million seed round led by High Tech Gründerfonds, super‑angel investors and Cambridge Ventures to advance a one‑time cryo‑based outpatient therapy that targets hunger reduction.

Context Obesity affects over 650 million adults worldwide and drives chronic disease, health‑care costs and premature death. Current medical options range from lifestyle counseling to invasive bariatric surgery, which carries significant risk and limited accessibility. A minimally invasive, outpatient solution could reshape treatment pathways.

Key Facts - Sedivention, headquartered in Magdeburg and Munich, announced €2.9 million in seed financing. The round was spearheaded by High Tech Gründerfonds, a German venture fund focused on deep‑tech, alongside a group of super‑angel investors and Cambridge Ventures, a UK‑based early‑stage investor. - The capital will fund pre‑clinical work, device engineering and the generation of first‑in‑human clinical data. The company plans a Phase I safety trial followed by a randomized controlled trial (RCT) with at least 120 participants to test efficacy in reducing hunger signals. - The therapy uses a cryo‑based (cold‑induced) intervention applied percutaneously in an outpatient setting. By temporarily deactivating hypothalamic pathways that regulate appetite, the procedure aims for a durable decrease in hunger without the need for repeat dosing. - Sedivention’s founders, Dr. Ute Nollert and Dr. Andreas Bröcker, have backgrounds in interventional radiology and metabolic research, positioning the team to bridge device engineering and clinical translation.

What It Means If the upcoming RCT demonstrates a statistically significant reduction in hunger scores compared with sham treatment, the therapy could become the first outpatient, single‑session alternative to bariatric surgery. For patients, this would mean lower procedural risk, reduced recovery time and potentially broader insurance coverage. For health systems, a scalable outpatient solution could lower long‑term obesity‑related expenditures.

Practical takeaways for readers: watch for trial enrollment announcements later this year; consider that the therapy is still experimental and not yet approved; and note that insurance reimbursement will depend on demonstrated safety and efficacy in the RCT.

Looking ahead, the success of Sedivention’s trial will determine whether cryo‑based hunger modulation moves from concept to clinic, setting a benchmark for future minimally invasive obesity interventions.